pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ALKSAlkermes plc.

$ALKS46.53-1.06%
Dublin 4, IEupdated 13h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
3
approvals ytd
1
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 1Phase 3: 1Marketed: 1Unknown: 2
1Phase 11Phase 31Marketed2Unknown
Marketed
(olanzapine + samidorphan l-malate)
Bipolar Disorder (Manic Depression)
Phase 3
alixorexton
Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Phase 1
valiloxybate ER
Narcolepsy
drug
LYBALVI
1 INDICATIONS AND USAGE LYBALVI is indicated for the trea…
D2-like dopamine receptor5-hydroxytryptamine receptor 2C
drug
VIVITROL
1 INDICATIONS AND USAGE Treatment with VIVITROL should be…
Opioid receptors; mu/kappa/delta

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Oct 28, 2026
earnings
$ALKS46.53-1.06%
20d ago
Alkermes plc. earnings
Alkermes plc.
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Alkermes plc. jobs →

News

  • An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
    biopharma_dive · 1mo ago
  • STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
    Novo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines
    stat · 1mo ago
  • STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
    The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
    stat · 1mo ago
  • With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
    Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
    fiercebiotech · 1mo ago
  • ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
    As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
    fiercebiotech · 2mo ago
  • 4 potential biotech M&A targets, plus a pretty sure bet from J&J
    Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
    biospace · 3mo ago
identifiers
ticker
$ALKS
SEC CIK
0001520262
country
IE
source
sec_tickers
top tags
Schizophrenia1
mentioned in
6news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 1m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?